Skip to main content
Erschienen in: Endocrine 3/2020

13.06.2020 | Original Article

The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma

verfasst von: Carla Vaz Ferreira Vargas, Lucieli Ceolin, Rafael Selbach Scheffel, Antônio Felippe Benini, Márcia Silveira Graudenz, Ana Luiza Maia

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Elevated serum levels of carbohydrate antigen 19.9 (CA19.9), a well-established tumor marker in pancreatic neoplasms, has been proposed as a prognostic marker of tumor aggressiveness in medullary thyroid carcinoma (MTC). A hypothesis of C-cell dedifferentiation has been raised. Here, we evaluated the expression of CA19.9 and CD133, a stem cell marker, in MTC tissues.

Methods

MTC samples from patients attending a university-based hospital were evaluated for CA19.9 and CD133 expression by immunohistochemistry. Clinical data were retrieved from medical records.

Results

Tumor specimens from 70 MTC patients (57.1% hereditary) were evaluated. The age at diagnosis was 36.1 ± 16.3 years, and 58.6% were female; 53% of patients had cervical and 20% distant metastases. CA19.9 staining was detected in 87% of the samples, but no association was observed with biochemical markers, tumor size, local or distant metastases (All P > 0.05). Remarkable, CA19.9 expression was higher in the metastasis than in primary tumor samples (P = 0.0002). CD133 was expressed in 90.5% samples, but no correlation was found with CA19.9. Interestingly, we identified three distinct expression patterns to CA19.9: individual, focal, and diffuse cells. Sporadic MTC was associated with the individual cell pattern (70.6%), while the hereditary form with the focal expression pattern (63.9%; P = 0.04). Remarkably, the diffuse pattern was associated with larger tumor size and distant metastases (P = 0.032).

Conclusions

The majority of samples stained for CA19.9, suggesting it is an MTC cell-intrinsic feature. Three distinct expression patterns were identified, which were associated with the hereditary or sporadic form, larger tumor size, and presence of metastases.
Literatur
2.
Zurück zum Zitat S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83(12), 2638–2648 (1998). 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 [pii]CrossRef S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83(12), 2638–2648 (1998). 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 [pii]CrossRef
5.
Zurück zum Zitat A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen, C. Dromain, J. Lumbroso, E. Baudin, M. Schlumberger, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158(2), 239–246 (2008). https://doi.org/10.1530/EJE-07-0667CrossRefPubMed A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen, C. Dromain, J. Lumbroso, E. Baudin, M. Schlumberger, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158(2), 239–246 (2008). https://​doi.​org/​10.​1530/​EJE-07-0667CrossRefPubMed
8.
Zurück zum Zitat R. Lamerz, Role of tumour markers, cytogenetics. Ann. Oncol. 10(Suppl 4), 145–149 (1999).CrossRef R. Lamerz, Role of tumour markers, cytogenetics. Ann. Oncol. 10(Suppl 4), 145–149 (1999).CrossRef
9.
Zurück zum Zitat V. Hess, B. Glimelius, P. Grawe, D. Dietrich, G. Bodoky, T. Ruhstaller, E. Bajetta, P. Saletti, A. Figer, W. Scheithauer, R. Herrmann, CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 9(2), 132–138 (2008). https://doi.org/10.1016/S1470-2045(08)70001-9CrossRefPubMed V. Hess, B. Glimelius, P. Grawe, D. Dietrich, G. Bodoky, T. Ruhstaller, E. Bajetta, P. Saletti, A. Figer, W. Scheithauer, R. Herrmann, CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 9(2), 132–138 (2008). https://​doi.​org/​10.​1016/​S1470-2045(08)70001-9CrossRefPubMed
11.
Zurück zum Zitat O. Micke, F. Bruns, R. Kurowski, E. Horst, A.F. deVries, J.W. Hausler, N. Willich, U. Schafer, Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J. Radiat. Oncol. Biol. Phys. 57(1), 90–97 (2003). S0360301603005248 [pii]CrossRef O. Micke, F. Bruns, R. Kurowski, E. Horst, A.F. deVries, J.W. Hausler, N. Willich, U. Schafer, Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J. Radiat. Oncol. Biol. Phys. 57(1), 90–97 (2003). S0360301603005248 [pii]CrossRef
13.
Zurück zum Zitat R. Elisei, L. Lorusso, C. Romei, V. Bottici, S. Mazzeo, C. Giani, E. Fiore, L. Torregrossa, A.C. Insilla, F. Basolo, A. Guerini, A. Menghi, A. Poletti, L. Cugudda, P. Vitti, Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. J. Clin. Endocrinol. Metab. 98(9), 3550–3554 (2013). https://doi.org/10.1210/jc.2013-1940CrossRefPubMed R. Elisei, L. Lorusso, C. Romei, V. Bottici, S. Mazzeo, C. Giani, E. Fiore, L. Torregrossa, A.C. Insilla, F. Basolo, A. Guerini, A. Menghi, A. Poletti, L. Cugudda, P. Vitti, Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. J. Clin. Endocrinol. Metab. 98(9), 3550–3554 (2013). https://​doi.​org/​10.​1210/​jc.​2013-1940CrossRefPubMed
15.
Zurück zum Zitat R. Elisei, L. Lorusso, P. Piaggi, L. Torregrossa, G. Pellegrini, E. Molinaro, L. Agate, V. Bottici, F. Pani, A. Cacciato Insilla, F. Casella, R. Ciampi, I. Tognetti, G. Materazzi, F. Basolo, C. Romei, Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. Eur. J. Endocrinol. 173(3), 297–304 (2015). https://doi.org/10.1530/EJE-15-0304CrossRefPubMed R. Elisei, L. Lorusso, P. Piaggi, L. Torregrossa, G. Pellegrini, E. Molinaro, L. Agate, V. Bottici, F. Pani, A. Cacciato Insilla, F. Casella, R. Ciampi, I. Tognetti, G. Materazzi, F. Basolo, C. Romei, Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. Eur. J. Endocrinol. 173(3), 297–304 (2015). https://​doi.​org/​10.​1530/​EJE-15-0304CrossRefPubMed
17.
Zurück zum Zitat D.R. Siqueira, M. Romitti, A.P. da Rocha, L. Ceolin, C. Meotti, A. Estivalet, M.K. Punales, A.L. Maia, The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr. Relat. Cancer 17(4), 953–963 (2010). https://doi.org/10.1677/ERC-09-0312CrossRefPubMed D.R. Siqueira, M. Romitti, A.P. da Rocha, L. Ceolin, C. Meotti, A. Estivalet, M.K. Punales, A.L. Maia, The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr. Relat. Cancer 17(4), 953–963 (2010). https://​doi.​org/​10.​1677/​ERC-09-0312CrossRefPubMed
18.
Zurück zum Zitat S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). https://doi.org/10.1089/thy.2014.0335CrossRefPubMedPubMedCentral S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). https://​doi.​org/​10.​1089/​thy.​2014.​0335CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (Eds.), AJCC Cancer Staging Manual (8th edition) (Springer International Publishing, American Joint Commission on Cancer, 2017) M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (Eds.), AJCC Cancer Staging Manual (8th edition) (Springer International Publishing, American Joint Commission on Cancer, 2017)
20.
Zurück zum Zitat A.L. Maia, D.R. Siqueira, M.A. Kulcsar, A.J. Tincani, G.M. Mazeto, L.M. Maciel, Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq. Bras. Endocrinol. Metab. 58(7), 667–700 (2014)CrossRef A.L. Maia, D.R. Siqueira, M.A. Kulcsar, A.J. Tincani, G.M. Mazeto, L.M. Maciel, Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq. Bras. Endocrinol. Metab. 58(7), 667–700 (2014)CrossRef
Metadaten
Titel
The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma
verfasst von
Carla Vaz Ferreira Vargas
Lucieli Ceolin
Rafael Selbach Scheffel
Antônio Felippe Benini
Márcia Silveira Graudenz
Ana Luiza Maia
Publikationsdatum
13.06.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02377-3

Weitere Artikel der Ausgabe 3/2020

Endocrine 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.